Brookline adjusted the firm’s price target on BioVie (BIVI) to $12 from $6 and keeps a Buy rating on the shares. The firm cites the company’s recent 1-for-10 reverse stock split for the target adjustment. It believes BioVie’s cash position provides a runway through fiscal 2026.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BIVI: